These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35711416)

  • 1. 6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice.
    Hou W; Lv L; Wang Y; Xing M; Guo Y; Xie D; Wei X; Zhang X; Liu H; Ren J; Zhou D
    Front Immunol; 2022; 13():906275. PubMed ID: 35711416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
    Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
    Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GII.P16-GII.2 Recombinant Norovirus VLPs Polarize Macrophages Into the M1 Phenotype for Th1 Immune Responses.
    Han JC; Li QX; Fang JB; Zhang JY; Li YQ; Li SZ; Cheng C; Xie CZ; Nan FL; Zhang H; Li ZX; Jin NY; Zhu GZ; Lu HJ
    Front Immunol; 2021; 12():781718. PubMed ID: 34868056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.
    Lindesmith LC; Beltramello M; Donaldson EF; Corti D; Swanstrom J; Debbink K; Lanzavecchia A; Baric RS
    PLoS Pathog; 2012; 8(5):e1002705. PubMed ID: 22615565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice.
    Wang X; Ku Z; Dai W; Chen T; Ye X; Zhang C; Zhang Y; Liu Q; Jin X; Huang Z
    Vaccine; 2015 Oct; 33(43):5779-5785. PubMed ID: 26424606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
    Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.
    Debbink K; Lindesmith LC; Donaldson EF; Swanstrom J; Baric RS
    J Virol; 2014 Jul; 88(13):7256-66. PubMed ID: 24741081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.
    Du J; Gu Q; Liu Y; Li Q; Guo T; Liu Y
    J Med Virol; 2021 Jun; 93(6):3974-3979. PubMed ID: 32869863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
    Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
    J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.
    Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY
    Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norovirus GII.4 strain antigenic variation.
    Lindesmith LC; Donaldson EF; Baric RS
    J Virol; 2011 Jan; 85(1):231-42. PubMed ID: 20980508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Jan; 11(2):. PubMed ID: 30678195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine.
    Chen W; Kang T; Yuan R; Shao C; Jing S
    Biotechnol Lett; 2020 Jul; 42(7):1211-1218. PubMed ID: 32088791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
    Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F
    Front Immunol; 2022; 13():1021500. PubMed ID: 36275772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice.
    Heinimäki S; Malm M; Vesikari T; Blazevic V
    J Immunol Res; 2018; 2018():3487095. PubMed ID: 29682589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults.
    Sherwood J; Mendelman PM; Lloyd E; Liu M; Boslego J; Borkowski A; Jackson A; Faix D;
    Vaccine; 2020 Sep; 38(41):6442-6449. PubMed ID: 32878708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.